Creation of a murine orthotopic hepatoma model with intra-abdominal metastasis
Gastroenterology and Hepatology from Bed to Bench,
Vol. 9 No. 3 (2016),
20 June 2016
,
Page 174-179
https://doi.org/10.22037/ghfbb.v0i0.841
Abstract
Aim: To create an orthotopic hepatoma model with local metastasis monitored with ultrasound could be created as a platform for testing new treatments.
Background: Hepatoma accounts for 25% of liver tumors in children with poor overall survival. Intraabdominal metastasis are present in 35% of patients at time of diagnosis. We hypothesized that an orthotopic tumor model with local metastasis could be created as a platform for testing treatment modalities and could be monitored with ultrasound.
Patients and methods: One million human hepatoma cells (Hep3B) were injected into the left lobe of the liver of immunocompromised mice. Tumor volume was monitored with high frequency-ultrasound until it reached 1,000mm3. At that time animals were sacrificed and examined for gross metastatic disease. Tumor sections were analyzed with hematoxylin and eosin (H&E) staining.
Results: Tumor formed in 8/15 mice. The tumor was detected as small as 19.59mm3 on ultrasound. Of the forming tumors, tumor size was 145±177.93mm3 at 60 days post-injection, 665±650.39mm3 at 67 days, and reached >1000mm3 by 76.6±9.9 days. At necropsy, four mice (50%) had tumor only within the liver, four (50%) had additional tumors in omentum, pelvis and peritoneum. H&E showed tumor within the normal liver parenchyma, with multiple mitotic figures, small areas of necrosis, and hemorrhage within the tumor.
Conclusion: We have successfully established an orthotopic hepatoma murine model, with a local metastatic rate of 50%. Non-invasive tumor monitoring is feasible via ultrasound.
- Hepatoma
- ultrasound
- metastatic
- mouse
- orthotopic
How to Cite
References
Agarwala S. Primary malignant liver tumors in children. Indian journal of pediatrics. 2012;79(6):793-800.
Meyers RL. Tumors of the liver in children. Surgical oncology. 2007;16(3):195-203.
Yu SB, Kim HY, Eo H, Won JK, Jung SE, Park KW, et al. Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World journal of surgery. 2006;30(1):43-50.
Moore SW, Hesseling PB, Wessels G, Schneider JW. Hepatocellular carcinoma in children. Pediatric surgery international. 1997;12(4):266-70.
Allan BJ, Wang B, Davis JS, Parikh PP, Perez EA, Neville HL, et al. A review of 218 pediatric cases of hepatocellular carcinoma. Journal of pediatric surgery. 2014;49(1):166-71; discussion 71.
Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, Malogolowkin MH, et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatric blood & cancer. 2011;56(7):1013-8.
Teicher BA. Human tumor xenografts and mouse models of human tumors: re-discovering the models. Expert opinion on drug discovery. 2009;4(12):1295-305.
Chiu B, Coburn J, Pilichowska M, Holcroft C, Seib FP, Charest A, et al. Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model. British journal of cancer. 2014;111(4):708-15.
Yao X, Hu JF, Daniels M, Yien H, Lu H, Sharan H, et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003;9(7):2719-26.
Ma SH, Chen GG, Yip J, Lai PB. Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice. Gene therapy. 2010;17(7):905-12.
Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. European journal of cancer. 2004;40(6):852-7.
Li ZY, Ni S, Yang X, Kiviat N, Lieber A. Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction. Molecular therapy : the journal of the American Society of Gene Therapy. 2004;9(5):650-7.
Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T, et al. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Molecular pharmacology. 2009;76(5):957-68.
Bagi CM, Andresen CJ. Models of hepatocellular carcinoma and biomarker strategy. Cancers. 2010;2(3):1441-52.
Kishimoto H, Urata Y, Tanaka N, Fujiwara T, Hoffman RM. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Molecular cancer therapeutics. 2009;8(11):3001-8.
Schmitz V, Tirado-Ledo L, Tiemann K, Raskopf E, Heinicke T, Ziske C, et al. Establishment of an orthotopic tumour model for hepatocellular carcinoma and non-invasive in vivo tumour imaging by high resolution ultrasound in mice. Journal of hepatology. 2004;40(5):787-91.
Wang Q, Luan W, Goz V, Burakoff SJ, Hiotis SP. Non-invasive in vivo imaging for liver tumour progression using an orthotopic hepatocellular carcinoma model in immunocompetent mice. Liver international : official journal of the International Association for the Study of the Liver. 2011;31(8):1200-8.
Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, Aronson D, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(12):2798-804.
- Abstract Viewed: 282 times
- PDF Downloaded: 222 times